China's cross-border drug deals reached $110B in H1, with AI as the fastest-rising segment 🔗

What happened: Chinese cross-border licensing deals for innovative drugs hit a record $110 billion in the first half of 2026, and the sector is now shifting toward AI-discovered candidates for the next wave. AI drug discovery was the standout new segment within that total, not the whole figure.

Why it matters: The capital base for AI drug discovery is tilting toward China. Western pharma is increasingly licensing de-risked, AI-originated Chinese assets rather than building the same capability internally, and the platform engines behind those assets run through most of the fortnight's largest deals.

Chai Discovery adds argenx and closes a $400M Series C 🔗

What happened: On July 15, Chai gave argenx early access to its generative antibody-design platform, in the same week that it closed a $400 million Series C at a $3.8 billion valuation. It is Chai's fourth disclosed pharma agreement in roughly seven months, after Eli Lilly, Pfizer, and Novartis.

Why it matters: One AI design startup is now working with four major drugmakers inside a year. Frontier molecular design has moved from demonstration to standard tooling in large-cap discovery groups.

Katalyze AI raises $10.5M for agentic pharma manufacturing 🔗

What happened: Katalyze closed a $10.5 million seed led by Bonfire Ventures for an agentic operating system that grounds AI agents in immutable production data across MES, LIMS, ELN, and SAP. It reports deployment at 5 of the 20 largest pharma companies.
Why it matters: The same thesis as Bora-Insilico, from the startup side. The next contested layer is governed, auditable AI on the plant floor, where an approximately correct answer has no value.

GE HealthCare and Catholic Health sign a $500M, 10-year Care Alliance 🔗

What happened: On July 16, GE HealthCare and Long Island's Catholic Health announced one of GE's largest US Care Alliances, roughly $500 million over ten years, covering AI-enabled imaging, cloud, and diagnostics across more than 40 sites.
Why it matters: AI imaging is being purchased at the health-system level on decade-long contracts. These procurement decisions set infrastructure that is difficult to change later.

BioPharma Dive: how AI-discovered drugs are performing in trials 🔗

What happened: BioPharma Dive reviewed AI-originated candidates in the clinic. Roughly 173 AI-originated programs are now in clinical development, up from about two dozen in 2023, but Phase 1 pass rates of 80 to 90% fall to around 40% in Phase 2, in line with traditional methods.
Why it matters: The funding thesis behind Chai, Insilico, and Isomorphic is running ahead of the clinical evidence. No AI-discovered drug has been approved yet, against roughly $20 billion invested. The next couple of years are where the platform claims meet trial data.

Pistoia Alliance poll: 42% of clinical teams report early AI returns 🔗

What happened: A live poll at the Clinical Trials Technology Congress found 42% of participants already seeing returns on AI, with another 23% expecting them, mostly through operational efficiency rather than direct cost savings. Trust and regulatory uncertainty were the leading barriers.
Why it matters: The question has shifted from whether AI works in trials to how the returns are measured. Regulators, not technical capability, are now the constraint.

UK biotech reaches a five-year funding high, concentrated in one deal 🔗

What happened: The BioIndustry Association reported UK biotech VC of £2.6 billion in H1 2026, the strongest in five years. Alphabet-owned Isomorphic Labs accounted for roughly 75% of the quarter's total. Excluding Isomorphic, UK biotech still raised £498 million in Q2, close to double the prior year.
Why it matters: The headline rests on concentration. A single AI drug discovery round is carrying a national figure, though the underlying mid-market recovery is real.